Ecovyst Inc. · NYSE:ECVT

Ecovyst — KeyBanc Industrials & Basic Materials Conference 2026

19 slides from Ecovyst's conference presentation, May 27, 2026

  1. Slide 1: KeyBanc Industrials & Basic Materials Conference

    KeyBanc Industrials & Basic Materials Conference May 27, 2026

  2. Slide 2: Legal Discussion

    Legal Discussion Continuing Operations Financial results are presented on a continuing operations basis, which excludes the Advanced Materials & Catalysts business, which was sold effective December 31, 2025. Forward-Looking Statements Some of the information contained in this presentation, the conf

  3. Slide 3: Legal Discussion: Supply Share and Industry Information

    Legal Discussion Supply Share and Industry Information Certain statistical information used in this presentation is based on independent industry publications, reports by research firms or other published independent sources. Some statistical information is also based on our good faith estimates whi

  4. Slide 4: Ecoservices

    Ecoservices Financial Highlights 2025 Sales - $724 Million 2025 Adjusted EBITDA1 - $172 Million Business Overview Demand Drivers Leading North American provider of sulfuric acid regeneration services • Customer ~10% reduction Achieveexpansion of alkylation units Regeneration in natural gas usage • G

  5. Slide 5: Acquisition of Calabrian Sulfur Dioxide & Derivatives Business

    Acquisition of Calabrian Sulfur Dioxide & Derivatives Business Calabrian provides sulfur dioxide and sulfur-based derivatives as essential inputs in the mining industry's cyanide-destruction processes and in other applications within water treatment, specialty chemicals and food preservatives Overvi

  6. Slide 6: Strategic Rationale

    Strategic Rationale • Expands Ecovyst’s product offering in sulfur chemistry and related derivatives into adjacent end uses • Enhances Ecovyst’s scale and diversifies end use and geographic exposure • Increases penetration into high-growth industries such as water treatment, mining, food and pharma

  7. Slide 7: First Quarter 2026 Financial Performance

    First Quarter 2026 Financial Performance

  8. Slide 8: Q1 2026 Key Highlights - Continuing Operations

    Key Highlights - Continuing Operations Q1 2026 Key Highlights $215 Mln $40 Mln $4 Mln Sales Adj. EBITDA Adjusted Free Cash Q1 2026 Q1 20261 Flow1,2 Q1 2026 $36 Mln 1.2x $237 Mln Share Repurchases Net Debt Leverage Liquidity4 Ratio1,3 1. See Appendix for reconciliations of Non-GAAP financial measures

  9. Slide 9: Financial Performance - Q1 2026

    Financial Performance - Q1 2026 First Quarter Financial Results - Continuing Operations First First $ % Quarter Quarter $ % Change Change ($ in millions) ($ in millions) 2026 2025 Change Change Sales Change Factors 71.9 50.2 Sales 215.0 143.1 71.9 50.2 Volume 32.2 22.5 Net Income (Loss) 5.7 (8.1) 13

  10. Slide 10: Cash & Leverage

    Cash & Leverage 1,4 4 2 1.2x 1.2x $40.0 Cash Generation Debt Profile • Q1 2026 Adjusted Free Cash Flow1 of $4 • Gross debt of $397 million million • Cash & cash equivalents of $163 million at • Q1 share repurchases of $35.7 million March 31, 2026 ◦ $146 million of share repurchase • Net Debt of $234

  11. Slide 11: Appendix

    APPENDIX

  12. Slide 12: Sales and Adjusted EBITDA Major Change Factors

    Sales and Adjusted EBITDA Major Change Factors Sales Sales Three months ended (in $ millions and %) March 31, 2026 Sales: $ % Volume 32.2 22.5 Price/Mix 39.7 27.7 Sales Change 71.9 50.2 Adjusted EBITDA Adj. EBITDA Three months ended (in $ millions and %) March 31, 2026 Adj EBITDA: $ % Volume/Mix 14.

  13. Slide 13: Reconciliation of Net Income from Continuing Operations to Adjusted EBITDA

    Reconciliation of Net Income (Loss) from Continuing Operations to Adjusted EBITDA from Continuing Operations Three months ended Twelve months ended ($ in millions, except %) March 31, 2026 March 31, 2025 March 31, 2026 December 31, 2025 Reconciliation of net income (loss) from continuing operations

  14. Slide 14: Reconciliation of Net Income (Loss) to Adjusted Net Income

    Reconciliation of Net Income (Loss) from Continuing Operations to Adjusted Net Income Three months ended ($ in millions, except share and per share amounts) March 31, 2026 March 31, 2025 Reconciliation of net income (loss) Tax Per share, Per share, Tax Per share, Per share, from continuing operation

  15. Slide 15: Reconciliation of Net Income to Adjusted Net Income (Year 2025)

    Reconciliation of Net Income from Continuing Operations to Adjusted Net Income Year ended ($ in millions, except share and per share amounts) December 31, 2025 Reconciliation of net income from Tax expense Per share, Per share, continuing operations to Adjusted Net Pre-tax (benefit) After-tax basic

  16. Slide 16: Descriptions for reconciliation of Non-GAAP financial measures

    Descriptions for reconciliation of Non-GAAP financial measures a. When asset disposals occur, we remove the impact of net gain/loss of the disposed asset because such impact primarily reflects the non-cash write-off of long-lived assets no longer in use. b. Relates to certain transaction costs, incl

  17. Slide 17: Adjusted Free Cash Flow

    Adjusted Free Cash Flow Three months ended Three months ended Full Year ($ in millions) March 31, 2026 March 31, 2025 2025 Net cash provided by operating activities 16.9 10.3 140.3 Less: Purchases of property, plant and equipment1 14.1 24.3 91.5 Free Cash Flow 2.8 (14.0) 48.8 Cash paid for debt fina

  18. Slide 18: Net Debt Leverage Ratio - Continuing Operations

    Net Debt Leverage Ratio - Continuing Operations ($ in millions, except %) March 31, 2026 December 31, 2025 Total debt 397.1 397.1 Less: Cash and cash equivalents 162.6 197.2 Net debt 234.5 199.9 Trailing twelve months: Net income from continuing operations 20.1 6.3 Adjusted EBITDA from continuing op

  19. Slide 19: Driving Progress

    Driving Progress BY DELIVERING RELIABLE SULFUR SOLUTIONS FOR CLEAN FUELS AND CRITICAL MATERIALS

Ecovyst — KeyBanc Industrials & Basic Materials Conference 2026 on 6ix